Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy Journal Article
| Authors: | Straus, D.; Collins, G.; Walewski, J.; Zinzani, P. L.; Grigg, A.; Sureda, A.; Illes, A.; Kim, T. M.; Alekseev, S.; Specht, L.; Buccheri, V.; Younes, A.; Connors, J.; Forero-Torres, A.; Fenton, K.; Gautam, A.; Purevjal, I.; Liu, R.; Gallamini, A. |
| Article Title: | Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy |
| Abstract: | We investigate the impact of granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (G-PP, N = 83) versus no G-PP (N = 579) on safety and efficacy of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) in the ECHELON-1 study of previously untreated stage III/IV classical Hodgkin lymphoma. G-PP was associated with lower incidence of ≥ grade 3 neutropenia (29% versus 70%) and febrile neutropenia (11% versus 21%). Fewer dose delays (35% versus 49%), reductions (20% versus 26%), and hospitalizations (29% versus 38%) were observed. Seven neutropenia-associated deaths occurred in the A + AVD arm; none received G-PP. A + AVD with G-PP was associated with decreased risk of a modified progression-free survival event by 26% compared with A + AVD alone (95% CI: 0.40–1.37). G-PP reduced the rate and severity of adverse events, including febrile neutropenia, reduced treatment delays, dose reductions, and discontinuations, and may thus improve efficacy outcomes. These data support G-PP for all patients treated with A + AVD. © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | growth factor; hodgkin lymphoma; brentuximab vedotin; frontline therapy; primary prophylaxis |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 61 |
| Issue: | 12 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2020-01-01 |
| Start Page: | 2931 |
| End Page: | 2938 |
| Language: | English |
| DOI: | 10.1080/10428194.2020.1791846 |
| PUBMED: | 32842815 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work